Pathos AI raises $365m for oncology drug development

Pathos AI has raised $365m successful a Series D backing circular arsenic it prepares to widen its AI-enabled level to beforehand the improvement of oncology drugs.

This concern boosts the company’s post-money valuation to an estimated $1.6bn.

The proceeds from the circular volition advancement Pathos AI's clinical-stage pipeline and further make its AI Foundation Model, specifically designed for oncology.

The institution is creating a multimodal instauration exemplary successful the field, utilising clinical, imaging and molecular information to refine the enactment of objective assets, survey design, find of biomarkers and therapeutic innovation.

Pathos AI CEO Iker Huerga stated: "Pathos was founded to alteration cause improvement by harnessing the afloat imaginable of multimodal information and AI.

"With this financing, we’re gathering 1 of the astir precocious AI engines, designed to accelerate development, deepen objective penetration and guarantee the close therapies scope the patients who request them most."

In March 2025, Pathos AI announced the archetypal taxable dosing successful its Phase Ib/IIa objective trial.

The proceedings is designed to measure CBP/p300 inhibitor and the company’s archetypal clinical-stage plus successful the pipeline, pocenbrodib, some arsenic monotherapy and successful conjunction with olaparib, abiraterone acetate oregon 177Lu-PSMA-617 to dainty metastatic castration-resistant prostate crab (mCRPC).

In a collaborative effort focusing connected crab cause discovery, Pathos AI, AstraZeneca and Tempus entered a multi-year agreement successful April 2025.

The concern is acceptable to make a large-scale, multimodal heavy learning exemplary that could expedite the recognition of cause targets and enactment the instauration of caller crab treatments. Tempus stands to summation $200m from information licencing and exemplary improvement fees arsenic portion of this deal.

Pathos AI is focused connected expediting innovation successful oncology done a caller exemplary for cause development.

By integrating multimodal data, AI and heavy objective insights, the institution aims to present caller treatments to patients much quickly.

"Pathos AI raises $365m for oncology cause development" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.